280 related articles for article (PubMed ID: 28729401)
1. JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.
Shien K; Papadimitrakopoulou VA; Ruder D; Behrens C; Shen L; Kalhor N; Song J; Lee JJ; Wang J; Tang X; Herbst RS; Toyooka S; Girard L; Minna JD; Kurie JM; Wistuba II; Izzo JG
Mol Cancer Ther; 2017 Oct; 16(10):2234-2245. PubMed ID: 28729401
[TBL] [Abstract][Full Text] [Related]
2. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 promotes proliferative vitreoretinopathy by inducing epithelial-mesenchymal transition via the JAK1/STAT3 signaling pathway.
Chen X; Yang W; Deng X; Ye S; Xiao W
Mol Vis; 2020; 26():517-529. PubMed ID: 32818015
[TBL] [Abstract][Full Text] [Related]
4. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
[TBL] [Abstract][Full Text] [Related]
5. Silencing of
Zhang P; Li Z; Yang G
Int J Mol Med; 2021 Dec; 48(6):. PubMed ID: 34713300
[TBL] [Abstract][Full Text] [Related]
6. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.
Geethadevi A; Nair A; Parashar D; Ku Z; Xiong W; Deng H; Li Y; George J; McAllister DM; Sun Y; Kadamberi IP; Gupta P; Dwinell MB; Bradley WH; Rader JS; Rui H; Schwabe RF; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P
Cancer Res; 2021 Oct; 81(20):5336-5352. PubMed ID: 34380633
[TBL] [Abstract][Full Text] [Related]
7. Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.
Smigiel JM; Parameswaran N; Jackson MW
Mol Cancer Res; 2017 Apr; 15(4):478-488. PubMed ID: 28053127
[TBL] [Abstract][Full Text] [Related]
8. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
9. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R
Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391
[TBL] [Abstract][Full Text] [Related]
10. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
Song L; Rawal B; Nemeth JA; Haura EB
Mol Cancer Ther; 2011 Mar; 10(3):481-94. PubMed ID: 21216930
[TBL] [Abstract][Full Text] [Related]
11. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M.
Yu Z; Li Z; Wang C; Pan T; Chang X; Wang X; Zhou Q; Wu X; Li J; Zhang J; Liu B; Zhu Z; Su L
Gastric Cancer; 2019 Sep; 22(5):955-966. PubMed ID: 30778797
[TBL] [Abstract][Full Text] [Related]
12. Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.
Kucia-Tran JA; Tulkki V; Scarpini CG; Smith S; Wallberg M; Paez-Ribes M; Araujo AM; Botthoff J; Feeney M; Hughes K; Caffarel MM; Coleman N
J Pathol; 2018 Mar; 244(3):283-295. PubMed ID: 29205362
[TBL] [Abstract][Full Text] [Related]
13. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition.
Guo L; Chen C; Shi M; Wang F; Chen X; Diao D; Hu M; Yu M; Qian L; Guo N
Oncogene; 2013 Nov; 32(45):5272-82. PubMed ID: 23318420
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal regulation of miR-206 and IL-6/STAT3 pathway mediates IL6-induced gefitinib resistance in EGFR-mutant lung cancer cells.
Yang Y; Wang W; Chang H; Han Z; Yu X; Zhang T
J Cell Mol Med; 2019 Nov; 23(11):7331-7341. PubMed ID: 31507089
[TBL] [Abstract][Full Text] [Related]
15. EPN3 plays oncogenic role in non-small cell lung cancer by activating the JAK1/2-STAT3 pathway.
Meng J; Zhang C; Zhu N; Zhang C; Liu M; Han Z; Li Y
Environ Toxicol; 2023 Aug; 38(8):1968-1979. PubMed ID: 37186036
[TBL] [Abstract][Full Text] [Related]
16. STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.
Bryson BL; Junk DJ; Cipriano R; Jackson MW
Cell Cycle; 2017 Feb; 16(4):319-334. PubMed ID: 27892764
[TBL] [Abstract][Full Text] [Related]
17. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.
Fossey SL; Bear MD; Kisseberth WC; Pennell M; London CA
BMC Cancer; 2011 Apr; 11():125. PubMed ID: 21481226
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling.
Goulet CR; Champagne A; Bernard G; Vandal D; Chabaud S; Pouliot F; Bolduc S
BMC Cancer; 2019 Feb; 19(1):137. PubMed ID: 30744595
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid re‑sensitises gefitinib‑resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial‑mesenchymal transition.
Yang X; Gao Y; Liu Q; Wan L; Liu H; Bian W; Du Y; Huang C
Oncol Rep; 2021 Feb; 45(2):459-468. PubMed ID: 33416163
[TBL] [Abstract][Full Text] [Related]
20. Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas.
Chen D; Chu CY; Chen CY; Yang HC; Chiang YY; Lin TY; Chiang IP; Chuang DY; Yu CC; Chow KC
J Pathol; 2008 Jul; 215(3):290-9. PubMed ID: 18491353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]